Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is GHRP-6 administered in research settings?

In research settings, GHRP-6 is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 DAC vs GHRP-6

Peptide Comparison

CJC-1295 DAC vs GHRP-6

Name: CJC-1295 DAC vs GHRP-6 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

1 providers listed

Full CJC-1295 DAC profile →

GHRP-6

Growth Hormone Releasing Peptide-6

PerformanceUnder clinical reviewResearch Only

Half-life: 15-60 minutes

39 providers listed

Full GHRP-6 profile →

Bottom line

CJC-1295 DAC carries stronger published evidence (RCT, 1 key studies) than GHRP-6 (Review, 1); both are research compounds.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

GHRP-6

Half-life

15-60 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	CJC-1295 DAC
Less frequent dosing (longer half-life)	CJC-1295 DAC
Lower typical price per mg	GHRP-6
More provider options (1 vs 39)	GHRP-6

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 DAC

GHRP-6

Mechanism Family

GH / IGF Axis

Half-life

6–8 days

15-60 minutes

FDA Status

not evaluated

Under clinical review

Admin Routes

subcutaneous

subcutaneous, intranasal

Availability

Research Only

Providers

1 listed

39 listed

FDA Update

—

Under clinical review

Avail. Notes

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

Hexapeptide GH secretagogue. No FDA approval. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Historical Phase 2 trials (Theratechnologies) but abandoned. Research chemical.

Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

GHRP-6

Review · 1 key study · dated evidence base — most recent 1997

Research Citations

CJC-1295 DAC

RCT2006 · Journal of Clinical Endocrinology and Metabolism

Effects of a single injection of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy…

GHRP-6

Review1997 · European Journal of Endocrinology

Growth hormone-releasing peptides

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About GHRP-6

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

Research Areas

GH release via GHS-R1a agonism — synergistic with GHRHpronounced appetite stimulation (ghrelin-mimetic effect)muscle recovery and GH pulse amplificationco-stimulation of cortisol and prolactin — less selective than ipamorelin

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

GHRP-6

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

IGF-1Fasting glucoseHbA1cCortisolInsulin

GHRP-6 produces stronger cortisol and prolactin stimulation than selective GH peptides. Research protocols measure IGF-1 for GH axis response and baseline cortisol. Glucose markers are standard given GH's effect on insulin sensitivity.

Used Together?

GHRP-6

Corticosteroids
Research notes that GHRP-6 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.

Price (per mg)

CJC-1295 DAC

$10.63/mg

$9.74 – $15.25 range

20 vendors

View price index →Find providers →

GHRP-6

$4.60/mg

$3.18 – $6.65 range

20 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 DAC

1 listed

Browse directory →

Providers offering

GHRP-6

39 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs GHRP-6 — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/ghrp-6

https://peptidebase.io/peptides/compare/cjc-1295-dac/ghrp-6 Methodology License Download JSON Download CSV